Holen Sie sich die Stockscreener-App
13.17
1.15%
0.15
Vorhandelsmarkt:
12.78
-0.39
-2.96%
Schlusskurs vom Vortag:
$13.02
Offen:
$13.02
24-Stunden-Volumen:
352.55K
Relative Volume:
0.41
Marktkapitalisierung:
$940.48M
Einnahmen:
$133.62M
Nettoeinkommen (Verlust:
$-177.37M
KGV:
-4.5571
EPS:
-2.89
Netto-Cashflow:
$23.50M
1W Leistung:
+4.19%
1M Leistung:
-13.47%
6M Leistung:
+42.53%
1J Leistung:
-31.51%
1-Tages-Spanne:
$12.93
$13.63
1-Wochen-Bereich:
$12.50
$13.74
52-Wochen-Spanne:
$6.92
$19.45
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Vergleichen Sie XNCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
13.17 | 929.76M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-29 | Hochstufung | Barclays | Underweight → Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Underweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Precision Trading with Xencor Inc. (XNCR) Risk Zones - Stock Traders Daily
Contrasting NRx Pharmaceuticals (NASDAQ:NRXP) & Xencor (NASDAQ:XNCR) - Defense World
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know - sharewise.com
Xencor, Inc. (XNCR) Stock Analysis: A Biotech Contender With 119.93% Potential Upside - DirectorsTalk Interviews
Activity Recap: Is Xencor Inc impacted by rising ratesQuarterly Profit Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Could Early XmAb819 Signals Reshape Xencor’s (XNCR) Broader T‑Cell Engager Investment Narrative? - Yahoo Finance
Market Catalysts: What is the target price for Xencor Inc stockMarket Activity Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
SG Americas Securities LLC Takes Position in Xencor, Inc. $XNCR - Defense World
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor (XNCR) Valuation Check After New Oncology And Autoimmune Pipeline Milestones - Yahoo Finance
Navigating the Valuation Gap in Xencor Shares - AD HOC NEWS
Xencor (NASDAQ:XNCR) Shares Down 7.1%Here's Why - MarketBeat
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving Average – Time to Sell? - Defense World
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Merger Talk: What hedge fund activity signals for Xencor Inc stockJuly 2025 Action & Accurate Intraday Trade Tips - Bộ Nội Vụ
Performance Recap: Can Xencor Inc stock outperform in a bear marketMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Weekly Earnings: Is Xencor Inc a top pick in the sector2025 Trading Recap & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
ImmunityBio, Xencor Drugs Win E.U. Nods - labusinessjournal.com
Xencor's Clinical Milestone Paves Way for Potential Revaluation () - aktiencheck.de
How supply shortages influence Xencor Inc. (XE9) stockJuly 2025 Summary & High Accuracy Investment Entry Signals - Улправда
Xencor, Inc.Common Stock (NQ: XNCR - FinancialContent
Xencor outlines 2026 pipeline plans for cancer and autoimmune drugs By Investing.com - Investing.com Nigeria
IPO Launch: Will Xencor Inc stock reach Wall Street targetsWeekly Trade Summary & Daily Momentum Trading Reports - Bộ Nội Vụ
Xencor, Inc. (XNCR) Stock Analysis: Biotech Innovator With Over 100% Potential Upside - DirectorsTalk Interviews
Will Xencor Inc. stock benefit from upcoming earnings reports2025 Price Targets & Weekly Return Optimization Alerts - Улправда
How Xencor Inc. stock reacts to Fed rate cuts2025 Top Decliners & High Accuracy Investment Entry Signals - Улправда
Will Xencor Inc. stock reach Wall Street targetsQuarterly Investment Review & Community Consensus Trade Alerts - Улправда
Is Xencor Inc. stock in correction or buying zoneQuarterly Profit Summary & AI Based Trade Execution Alerts - ulpravda.ru
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - BioSpace
Xencor expects to have sufficient cash resources to fund research and development programs and operations through 2028 - marketscreener.com
Xencor Expects To Have Sufficient Cash Resources To Fund Research And Development Programs And Operations Through 2028 - TradingView — Track All Markets
Xencor outlines 2026 pipeline plans for cancer and autoimmune drugs - Investing.com
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR) - The Globe and Mail
Star TribuneXencor, Inc.Common Stock (Nasdaq:XNCR) Stock Quote - FinancialContent
Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy - MSN
Xencor (NASDAQ:XNCR) Trading Down 7.1%Time to Sell? - MarketBeat
Incyte marks trial win for Xencor lymphoma drug (INCY:NASDAQ) - Seeking Alpha
Trading the Move, Not the Narrative: (XNCR) Edition - Stock Traders Daily
The Truth About Xencor Inc: Is This Quiet Biotech About To Explode? - AD HOC NEWS
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 (NASDAQ:XNCR) - Seeking Alpha
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR) - Yahoo Finance
Xencor issued US patent for Xtend FC domain - MSN
Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 73,367 Shares - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares of Stock - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Xencor SVP Desjarlais sells $1.15 million in shares By Investing.com - Investing.com Nigeria
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):